Early graft dysfunction following adult-to-adult living-related liver transplantation: Predictive factors and outcomes

Table 2 Univariate analysis of pre-transplant clinical data in the two groups: EGD vs non-EGD

	EGD (10 pts)	Non-EGD (63 pts)	P value
Pre-transplant serum bilirubin (mg/dL)	8.71 (1.27-29.21)	2.01 (0.28-24.82)	0.013
1Pre-transplant serum albumin (g/dL)	2.6 (2.2-3.3)	2.8 (1.31-4)	NS
Pre-transplant serum sodium (mEq/L)	133 (122-145)	138 (126-144)	NS
Pre-transplant INR	1.38 (1.27-2.55)	1.22 (0.81-2.55)	0.001
Pre-transplant platelets (mmc)	48 000 (22 000-60 000)	71 000 (24-400)	0.007
Pre-transplant WBC (mmc)	4575 (1700-7200)	4200 (1500-15 500)	NS
Child-Pugh score, points	10.00 (8-12)	8.0 (5-12)	NS
MELD score	20.50 (12-40)	15.0 (6-28)	NS
Meld-Na score	24.25 ± 7.9	18.13 ± 5.8	0.004
Steatosis (No/Macro 1%-2%/Macro 10%-20%/Macro 25%-30%)	(6/2/2/0)	(35/15/9/4)	NS
Liver volume (mL)	780 (590-1186)	1016 (557-1482)	NS
Spleen volume (mL)	983 (648-1382)	709 (161-2711)	NS
S/LVR	0.96 (0.55-2.34)	0.78 (0.13-2.95)	NS
GRDWR	1.26 (0.79-1.59)	1.48 (0.81-2.96)	NS
GS/SLV	59.52 (37.34-70.19)	68.5 (38.7-132.6)	NS

¹Neither group of patients received albumin supplementation before transplant. S/LVR: Spleen/liver volume ratio; GRDWR: Graft-to-recipient body weight ratio; GS/SLV: Graft-to-recipient standard liver volume. Data are expressed as mean (range), or mean ± SD.